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Valproic Acid (VPA) is a histone deacetylase inhibitor that holds promise for cancer therapy. Here, we investigate whether VPA
treatment induces neuroendocrine diﬀerentiation of Prostate Cancer (PCa). A tissue microarray of VPA-treated and untreated
tumor xenografts and cell lines of human PCa (LNCaP, C4-2, DU145, and PC-3) were generated and were analyzed by
immunohistochemical analysis (IHC) for NE markers chromogranin A (CgA), synaptophysin, and NCAM (neural cell adhesion
molecule). Western blot analysis for CgA was performed to conﬁrm the results of the TMA. IHC analysis did not reveal any
induction of CgA, synaptophysin, or NCAM in any xenograft after VPA treatment in vivo. In vitro, VPA treatment induced little
synaptophysin expression in C4-2 and PC-3 cells and NCAM expression in LNCaP and PC-3 cells. In the case of CgA, VPA
treatment decreased its expression in vitro in a dose-dependent manner, as determined by western blot analysis. Thus our data
demonstrates that VPA does not induce NE diﬀerentiation of PCa cells in the physiologically relevant in vivo setting.
1.Introduction
Histone acetylation and deacetylation by histone acetyl
transferases and histone deacetylases is involved in the epi-
genetic regulation in human cells [1, 2]. Recently, this post-
translational modiﬁcation has become a popular molecular
target for cancer therapy. HDAC inhibitors (HDACIs) have
demonstrated signiﬁcant antitumor activity by hyperacety-
lation of nucleosomal histones resulting in reexpression
of repressed genes that produce growth arrest, terminal
diﬀerentiation, and/or apoptosis in carcinoma cells [3].
Valproic Acid (VPA), an HDACI and an antiepileptic agent,
causes marked decrease in proliferation of Prostate Cancer
(PCa) cells in vitro and signiﬁcant reduction in tumor
volume in vivo [4, 5]. Multiple pathways including cell cycle
arrest, apoptosis, angiogenesis, and senescence contribute to
the antitumor eﬀects of VPA.
Neuroendocrine (NE) cells are the third and minor
epithelial cell type in prostate, in addition to the more
abundant luminal secretory cells and basal cells [6]. NE
cells have dual properties of neurons and endocrine cells
and are believed to be involved in the regulation, secretion
and diﬀerentiation of other prostatic cells [7]. Conventional
adenocarcinoma with focal NE cells represents the most
common type of PCa. Small cell PCa and prostatic carcinoid
are relatively rare and are considered pure NE tumors with
ap o o rp r o g n o s i s[ 8]. Neuroendocrine diﬀerentiation thus
has been suggested as a poor prognostic sign by some
authors, but the exact role of NE diﬀerentiation of the
prostate remains unclear, and its prognostic importance2 Journal of Biomedicine and Biotechnology
in prostate cancer still remains controversial [7, 9]. The
characteristics of NE diﬀerentiation in PCa are very much
similar to those seen in patients who develop this histologic
phenotype in non-small-cell lung cancer [10]. NE cells in
prostateexpressNEmarkerssuchasChromograninA(CgA),
synaptophysin, B-tubulin, neural cell adhesion molecule
(NCAM or CD56), neuron speciﬁc enolase (NSE), and
so forth. NE cells can be generally identiﬁed by electron
microscopy or immunohistochemical (IHC) staining with
antibodies for NE markers [11].
Recently, some studies have documented increased neu-
roendocrine markers after in vitro treatment of prostate can-
cer cell lines with HDACIs [9, 12] indicating neuroendocrine
transdiﬀerentiation. In contrast, studies done in neuroen-
docrine tumors such as carcinoid, pheochromocytoma, and
small cell lung cancers have shown VPA and other HDACIs
to exert antitumor eﬀects [13–15]. VPA has been shown to
promote apoptosis, reduce NE phenotype and expression of
NEmarkers,andissuggestedasapromisingtherapyforthese
tumors[16,17].ThustheroleofHDACI’sinneuroendocrine
diﬀerentiation still remains unclear and has thus warranted
further investigation.
The goal of this study is to carefully determine whether
VPA induces NE diﬀerentiation in the PCa cell lines, in vivo
and in vitro, by studying a variety of markers associated with
NE diﬀerentiation in numerous PCa cell and tumor models.
Markers including CgA, synaptophysin, and NCAM were
quantiﬁedbyIHCinatissuemicroarray(TMA)formatfrom
several VPA-treated human PCa cells grown in vitro and in
vivo as tumor xenografts in nude mice.
2.MaterialsandMethods
2.1. Tumor Cell Lines. Human prostate cancer cell lines
LNCaP, PC-3, and DU145 were obtained from American
Type Culture Collection (Manassas, VA), and C4-2 line was a
giftfromDr.LelandChung(EmoryUniversity,Atlanta,GA).
All the cells were grown in RPMI 1640 with L-glutamine
(Cellgro, Herndon, VA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Life Technologies, Inc.,
Carlsbad, CA), 5μg/mL ciproﬂoxacin hydrochloride (U.S.
Biological, Swampscott, MA), and 50μg/mL gentamicin
(Quality Biological, Inc., Gaithersburg, MD). Cells were
allowed to grow until 80% to 90% conﬂuent and harvested
with 0.05% trypsin/0.53mmol/L EDTA (Cellgro, Herndon,
VA) before each subsequent passage.
2.2.EstablishmentofTumorXenografts. Celllinesweregrown
to 80% to 90% conﬂuent and harvested. Cells were resus-
pended in 1x phosphate-buﬀered saline (pH 7.4; BioSource,
Rockville, MD), mixed 1x with Matrigel (BD Biosciences,
Palo Alto, California), and injected (1 × 106 per injection)
subcutaneously into the lateral ﬂanks of male athymic nu/nu
mice. Once palpable tumors were established, animals were
randomized into control and treatment arms.
2.3. Valproic Acid Treatment. VPA (1mol/L; VPA sodium
salt; Sigma, St. Louis, MO) stock was made in PBS and ﬁlters
sterilized through a 0.22μm ﬁlter. For in vitro experiments
cell lines were treated with 0, 0.6, and 1.2mM VPA for
14 days. Medium was replaced every 48 hours with fresh
medium containing VPA. For in vivo experiments, animals
received 0.4% w/v VPA in drinking water. This has been
shown to produce blood levels in mouse [4]c o m p a r a b l et o
FDA approved levels in humans [18]. Animals in treatment
arm were treated for 35 days before excision of tumors. In
in vivo experiments, chronic treatment implies to long-term
treatment with regards to life span. We considered 35 days of
treatment in nude mice (with life span of 1 year approx. in
our experience) as long-term treatment. This period would
correspond to years of treatment in humans.
2.4. Western Immunoblotting. Cells treated with diﬀerent
doses of VPA were harvested by trypsinization and resus-
pended with 5 volumes of cold lysis buﬀer (RIPA buﬀer,
Cat# R0278, Sigma, St. Louis, MO) and supplemented
with protease inhibitor cocktail (Roche, Indianapolis, IN,
USA). Equal amounts of proteins were separated by SDS-
PAGE and the resolved proteins transferred to nitrocellulose
membrane. The membrane was blocked for an hour in
blocking buﬀer [100mM Tris-HCl (pH 7.5), 150mM NaCl,
0.1% Tween 20] with 5% nonfat dry milk and then
incubated with rabbit antiacetylated histone H3 (Upstate,
Charlottesville, VA) overnight followed by antirabbit IgG
peroxidase conjugate (Sigma, St. Louis, MO) for 1.5 hours
at room temperature. Immunoreactive bands were detected
using the enhanced chemiluminescence plus western blot-
ting detection system (Amersham Biosciences, Piscataway,
NJ) according to the manufacturer’s instructions. Anti-
Cip1/WAF1/p21 mouse monoclonal IgG (Upstate, Char-
lottesville, VA), CgA (LK2H10) mouse monoclonal antibody
(Santa Cruz Biotechnology, INC., Santa Cruz, CA), and
antimouse IgG peroxidase (Sigma, St. Louis, MO) were used
to test p21 and CgA expression separately. Monoclonal anti-
β-actininmouse(Sigma,St.Louis,MO)andantimouseIgG-
peroxidase (Sigma, St. Louis, MO) were used to normalize
protein loading.
2.5. TMAs: Construction and IHC Staining. For in vitro
models, cells were harvested and washed in PBS. Resulting
cell pellets were incubated for 1-2hr in Bouin’s ﬁxative
(75% saturated picric acid, 20% formalin (40%), 5% acetic
acid, rinsed with 70% ethanol, and dehydrated according to
standard procedures with ethanol and xylene. Cell pellets >
5mm were split in order to achieve suﬃcient dehydration.
Cells were embedded in paraﬃn following 90min of incu-
bation in liquid paraﬃna t6 0
◦C. For in vivo models, tumors
were excised and portioned on day 35. Portions were either
immediately frozen in liquid nitrogen and stored at −80
◦C
or ﬁxed in buﬀered formalin and subsequently embedded in
paraﬃn.
A tissue microarray (TMA) of the paraﬃne m b e d -
ded materials was generated as described previously [19].
Each array block also contained control normal human
prostate tissues and animal xenograft tissues such as bladder,
kidney, lung and spleen. Immunohistochemical stains forJournal of Biomedicine and Biotechnology 3
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Figure 1: Chromogranin A staining in prostate cancer cells treated with VPA in vitro. (a): Representative images of CgA staining for cell
pellet sections from control and VPA-treated groups: LNCaP, C4-2, PC-3, and DU-145 (Scanned at 20X magniﬁcation using the APERIO
imaging system). The tissue specimens of normal human prostate were positive internal controls for CgA staining. (b) Western blot analysis
of cells treated in vitro. LNCaP, C4-2, DU-145, and PC-3 cells treated with VPA show induction of acetyl-H3, verifying HDACI activity, and
downregulation of the NE marker CgA.4 Journal of Biomedicine and Biotechnology



















































Figure 2: Synaptophysin staining in prostate cancer cells treated with VPA in vitro. (a): Representative images of synaptophysin staining
for cell pellet sections from control and VPA-treated groups: LNCaP, C4-2, PC-3, and DU-145 (Scanned at 20X magniﬁcation using the
APERIO imaging system). (b) Weighted scoring of IHC staining for synaptophysin (∗ indicates P<.05).
chromogranin A (Clone LK2H10, Ventana, Tucson, AZ),
synaptophysin (Polyclonal, Cell Marque, Rocklin, CA), and
NCAM/CD56 (123C3.D5, Cell Marque, Rocklin, CA) were
performed separately on sections cut from the TMA. Stained
TMA slides were scanned (at 20x magniﬁcation setting)
using the APERIO imaging system and the images were
uploaded and viewed using TMAJ [20, 21]. Each array spot
was then formed into a composite image for viewing and
scoring on a personal computer monitor.
2.6. Scoring of IHC Staining. IHC specimens were provided
to pathologist for scoring. The identity of sample and
treatment was blinded to the scorer. The specimens showed a
varying degree of staining intensity and percentage of cells
staining. Therefore, a combined intensity and percentage
positive scoring method was used [22]. Strong intensity
staining was scored as 3, moderate as 2, weak as 1, and
negative as 0. For each intensity score, the percentage of cells
with that score was estimated visually. A combined weighted
score consisting of the sum of the percentage of cells staining
at each intensity level was calculated for each sample, for
example, a case with 50% strong staining, 20% moderate
staining, and 10% weak staining would receive a score as
follows: (50 × 3+2 0× 2+1 0× 1) = 200. The maximum
score is 300.
2.7. Statistical Analysis. Analysis was done using GraphPad
Prism 4.0. Data is plotted as means(SE). One way ANOVA
with post-hoc testing was done to evalauate diﬀerences in
mean staining score between diﬀerent groups.
3. Results
3.1. In Vitro. The most reliable method to assess NE
diﬀerentiation in PCa is the detection of CgA in tumor cells.
IHCstainingforCgAandtwootherneuroendocrinemarkers
synaptophysin and NCAM were done.
3.1.1. Chronic VPA Treatment Reduces CgA Expression. The
IHC staining of sections constructed of cell lines treated for
14 days with VPA was not able to detect any expression of
CgA (Figure 1(a)). In order to verify the absence of CgA byJournal of Biomedicine and Biotechnology 5


















































Figure 3: NCAM staining in prostate cancer cells treated with VPA in vitro. (a): Representative images of NCAM staining for cell pellet
sections from control and VPA-treated groups: LNCaP, C4-2, PC-3, and DU-145 (scanned at 20X magniﬁcation using the APERIO imaging
system). (b) Weighted scoring of IHC staining for NCAM (∗ indicates P <.05).
the IHC in all the cell lines tested, we performed Western
blot analysis (Figure 1(b)). Results revealed CgA expression
in these cell lines; however, CGA protein levels were reduced
in a dose-dependent manner after VPA treatment. Histone 3
acetylation conﬁrmed VPA activity.
3.1.2. Chronic VPA Treatment and Synaptophysin and NCAM
Expression. Chronic in vitro treatment of C4-2 cells with
VPA resulted in increased synaptophysin expression (mean
weighted score 65(±4) at 1.2mM versus 34(±4) at 0.6mM
(P =.002) and 18(±4) at 0mM (P<.001)). Signiﬁcantly
increased expression was also found in PC-3 cells treated at
1.2mM(meanweightedscore68(±2)versus10(±2)inother
two groups, P<.001). However, synaptophysin expression
wasnotalteredinLnCapandDU145celllinesfollowingVPA
treatment (Figure 2).
Chronic in vitro treatment of VPA increased the expres-
sion of NCAM in LNCaP (weighted score 8(±3) at 0mM
versus 40(±3) at 0.6mM, (P<.001); 40(±3) at 0.6mM
versus 65(±4) at 1.2mM, (P =.002). In PC-3 cells, no
expression of NCAM was seen at 0 and 0.6mM VPA, but
slight expression was seen at 1.2mM (mean weighted score
20(±5)). None or very little NCAM staining was seen in C4-
2 and DU145 at either dose (Figure 3).
3.2. In Vivo
3.2.1. Chronic VPA Treatment In Vivo Does Not Induce
the Expression of CgA, Synaptophysin, or NCAM. Unilateral
tumor xenografts were established in 20 animals each for
everycellline.Halfoftheanimalswererandomizedtoreceive
0.4% VPA in drinking water. We have shown previously that
administration of 0.4% VPA in mouse drinking water can
achieve plasma VPA levels similar to the levels obtained in
human patients [4]. VPA treatment at these levels was shown
to induce acetyl H3K9, p21, and reduce tumor volume,
thus conﬁrming the pharmacologic activity of VPA [4].
Animals were sacriﬁced, and tumors were harvested on day
35. To investigate the eﬀects of VPA on NE markers of PCa
tumors in vivo, we evaluated expression of NE markers by
IHC on the excised tumors. IHC did not reveal any CgA6 Journal of Biomedicine and Biotechnology
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Figure 4: Continued.Journal of Biomedicine and Biotechnology 7
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Figure 4: Chromogranin A staining in prostate xenografts animals treated with or without VPA. (a): Representative images of CgA staining
for xenograft sections from control and VPA-treated groups: LNCaP, C4-2, PC-3, and DU-145 (Scanned at 20X magniﬁcation using the
APERIO imaging system). The tissue specimens of human pancreas and human prostate were positive internal controls for CGA staining,
while another human prostate section served as a negative control. (b) Synaptophysin staining in prostate xenografts animals treated with or
without VPA. A: Representative images of synaptophysin staining for xenograft sections from control and VPA-treated groups: LNCaP, C4-2,
PC-3, and DU-145 (Scanned at 20X magniﬁcation using the APERIO imaging system). The tissue specimens of human pancreas and mouse
colon were positive internal controls for synaptophysin staining, while mouse bladder as negative internal controls. (c) NCAM staining in
prostate xenografts animals treated with or without VPA. (a): Representative images of CD56 staining for xenograft sections from control
and VPA-treated groups: LNCaP, C4-2, PC-3, and DU-145 (scanned at 20X magniﬁcation using the APERIO imaging system). The tissue
specimens of human colon carcinoid and normal human prostate were positive internal controls for NCAM staining, while mouse bladder
was a negative control.
staining in either treatment or control arms in all cell lines
(Figure 4(a)). TMAs from C4-2 tumors revealed decreased
expression of both synaptophysin (mean weighted score
47(±10) versus 15(±5), P <.001) and NCAM (44(9) versus
5(6), P =.002) in treatment arms (Figure 4(b)). None of the
other arms revealed any signiﬁcant staining (weighted scores
less than 30) for NCAM or synaptophysin (Figures 4(b) and
4(c)). Thus VPA does not induce any NE markers in the
physiologically relevant in vivo setting.
4. Discussion
NE cells are considered to be derived from local stem cells
and are an example of normal, terminally-diﬀerentiated cells
without proliferative activity [6]. NE cells in tumor lesions
are phenotypically similar to NE cells in normal prostate
epithelium in terms of expression of neuropeptides and
biogenic amines. Furthermore, dual epithelial characteristics
such as prostatic acid phosphatase and/or PSA production
and NE marker expression, such as CgA, are frequently
coexpressed in the malignant phenotype of NE cells [23].
Studies evaluating the role of focal NE diﬀerentiation in PCa
prognosis have reported varied results: some reports indicate
a negative correlation with prognosis while some show little
or no relationship to prognosis [10, 23–28].
Histone deacetylase inhibitors are a promising new
c l a s so fc a n c e rt h e r a p yw h i c hh a v ea n t i p r o l i f e r a t i v ea n d
prodiﬀerentiation properties. For prostate cancer, it was
recently reported that HDAC gene expression is elevated in
tumors. Moreover, high expression levels of HDAC2 were
associated with poor prognosis [29]. Thus VPA, which is
capable of inhibiting HDACs classes I and IIa, may be a good8 Journal of Biomedicine and Biotechnology
optionforPCatherapy.Inpreclinicalmodels,VPAtreatment
leads to proliferation arrest and diﬀerentiation and apoptosis
of cancer cells of various tissue origin, while nominal eﬀects
were reported in normal cells [2, 4, 5]. However, Valentini
et al. reported VPA to cause an increase in the secretion of
NSE in LNCaP cells (in vitro) which may indicate an NE
diﬀerentiation [12]. In order to better understand the role
of VPA in possibly stimulating NE diﬀerentiation in PCa
cell models, we selected the clinically recommended panel of
antibodies for the IHC investigation of NE cells in multiple
PCa cell lines and xenograft tumors.
Chromogranin A or parathyroid secretory protein 1
is a member of the chromogranin-secretogranin family
and forms the major constituent in neurosecretory pep-
tide containing dense core granules in NE cells. CgA is
highly expressed by cells of neuroendocrine origin, both
normal and tumoral, functional and nonfunctional. While
Neuron Speciﬁc Enolase (NSE) has also been used as an
NE marker, it is known to be expressed in a variety of
non-NE cells and tumors, which has led researchers to
question its speciﬁcity [30, 31]. Serum CgA levels, on the
other hand, have been reported to be better predictors of
neuroendcocrine diﬀerentiation than NSE [32, 33]. Thus,
CgA now is widely regarded as an excellent and more
speciﬁc marker of NE diﬀerentiation. In our study, CgA
expression was not detected by IHC in either control or
treated groups in human prostate cell lines of LNCaP, C4-2,
PC-3, and DU145 in vitro or in vivo. Western blotting, being
more sensitive, revealed low CgA expression in these cell
lines; which reduced further with VPA treatment in a dose-
dependent manner. Histone acetylation and p21 induction
(data not shown) conﬁrmed that active VPA doses were
achieved as we have previously demonstrated [5, 34]. Our
results are further corroborated by similar reduction in NE
markers and NE morphology in NE tumors after treatment
with HDACIs [13, 14, 16] .T h e s es t u d i e si nf a c tr e p o r t
apoptotic eﬀects of VPA on neuroendocrine cells. Yu et
al. have previously demonstrated CgA to be an important
neuropeptide promoting the growth of prostate cancer cells
and its suppression leading to programmed cell death in
multiple prostate cell lines [35]. Gong et al. later found
antiapoptotic eﬀects of CgA to be dependent on a Protein
KinaseB/Akt(anantiapoptoticproteinorprosurvivalfactor)
mediated pathway [36]. Also HDACIs have been known to
downregulate Akt phosphorylation in prostate cancer cells
[37] Taken together, it suggests a link between HDACI’s-
mediated apoptosis and CgA inhibition. Further studies will
be required to determine the contribution of CgA and Akt to
the VPA therapeutic eﬀect.
Synaptophysin and NCAM are other speciﬁc and fairly
sensitive markers for NE diﬀerentiation [38, 39]. In in
vitro experiments, these markers showed varying trends
(increased synaptophysin staining in C4-2 and PC-3 cells
but unaltered in LnCaP and DU145; increased NCAM in
LnCAP and PC-3 cells but unaltered in C4-2 and DU145),
and no consistent pattern was seen. In in vivo experiments,
the staining did not reveal any signiﬁcant expression of these
markersinanyofthexenograftsexceptinC4-2tumorswhere
it revealed a downward trend on treatment.
5. Conclusion
The ﬁndings in our study do not support any neuroen-
docrine diﬀerentiating role of VPA. On the contrary, CgA,
a very speciﬁc marker, was reduced in all studied cell
lines, following chronic VPA treatment. Synaptophysin and
NCAM showed some inconsistent induction following VPA
treatment in some cell lines but, in vivo, VPA treatment did
not induce any signiﬁcant expression of any NE markers.
0.4% VPA in mouse drinking water can achieve plasma
VPA levels similar to the therapeutic levels obtained in
human patients. TMAs from xenografts of diﬀerent cell
lines either did not stain for NE markers or had very little
staining without any induction on VPA treatment. Thus,
our data clearly demonstrates that VPA does not induce NE
diﬀerentiation of PCa cells in the physiologically relevant in
vivo setting.
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